Clinical features of patients with Behçet uveitis receiving infliximab (IFX) before and after treatment
| Patient no | Age (years) | Gender | Interval between onset and IFX (months) | Treatment before IFX administration | Uveitis attacks | Extraocular findings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before IFX | IFX6M | IFX12M | Before IFX | IFX6M | IFX12M | |||||
| 1 | 64 | F | 65 | PSL, MTX | 6 | 0 | 0 | O, S, I | – | – |
| 2 | 49 | M | 83 | PSL, MTX, CsA | 4 | 1 | 0 | O | – | – |
| 3 | 35 | M | 66 | Col, PSL | 8 | 1 | 0 | O, G, S | – | – |
| 4 | 69 | F | 132 | Col, PSL | 4 | 1 | 1 | O | – | – |
| 5 | 49 | F | 36 | Col, PSL, CsA | 5 | 1 | 0 | O, S | – | – |
| 6 | 42 | F | 61 | Col, PSL | 4 | 0 | 0 | O | – | – |
| 7 | 26 | M | 159 | Col, PSL, MTX | 0 | 0 | 0 | O, S | – | – |
| 8 | 53 | M | 36 | Col, PSL | 9 | 0 | 0 | S, J | – | – |
| 9 | 33 | M | 120 | Col, PSL, CsA | 1 | 0 | 0 | O | – | – |
| 10 | 44 | M | 24 | Col, PSL, CsA | 4 | 0 | 0 | O | – | – |
| 11 | 38 | F | 14 | Col, PSL | 1 | 0 | 0 | O, G, S | – | – |
| 12 | 54 | M | 58 | Col | 3 | 1 | 0 | O, S | – | – |
| 13 | 26 | M | 15 | Col | 2 | 0 | 0 | O, G, S | – | – |
| 14 | 26 | M | 7 | Col, PSL, CsA | 3 | 2 | 4 | O | O | O |
| 15 | 71 | M | 180 | Col, PSL | 4 | 2 | 1 | O, S | O | – |
| 16 | 43 | M | 36 | Col, PSL, CsA | 3 | 0 | 0 | O, G, S | – | – |
| 17 | 62 | F | 46 | Col, PSL | 4 | 1 | 0 | O, G | O | – |
| 18 | 40 | F | 36 | Col, PSL, CsA | 3 | 0 | 0 | O | – | – |
| 19 | 24 | M | 30 | Col, PSL | 3 | 0 | 0 | O, G, S | – | – |
| 20 | 38 | F | 89 | Col, PSL | 1 | 0 | 0 | S | – | – |
Col, colchicine; CsA, ciclosporin; G, genital ulcer; I, intestinal symptom; IFX6M, IFX12M, 6 and 12 months after receiving infliximab; J, joint symptom; MTX, methotrexate; O, oral aphthae; PSL, prednisolone; S, skin lesion.